North America RNA Interference Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
North America · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$2.65 BnPlaceholder estimate
Estimate 2025$3.15 Bn54.6% of the global market
Projected 2034$14.94 Bn 374.9%Adds $11.80 Bn over 9 forecast years
CAGR 2025–203418.9%Faster than 86% of 180 Pharmaceuticals markets here
Key players5
North America is 54.62% of the global market.
Among regions, the largest is North America (this report) at $3.15 Bn.
27 in North AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The North America RNA Interference Therapeutics Market Analysis Executive Summary
RNA interference therapeutics use small RNA molecules to switch off disease-causing genes, used in rare, heart and liver diseases.
Key segments of the RNA Interference Therapeutics market include molecule (siRNA, Antisense Oligonucleotides and microRNA) and indication (Rare Genetic Diseases, Cardiovascular and Liver Diseases).
North America RNA Interference Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
North America RNA Interference Therapeutics Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the RNA Interference Therapeutics market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the RNA Interference Therapeutics market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the RNA Interference Therapeutics market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for RNA Interference Therapeutics Market in North America
The RNA Interference Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for RNA Interference Therapeutics Market in North America
RNA Interference Therapeutics in North America: rules, payment and research
In the countries we cover here, medicines are approved by Health Canada (Canada)[1] and FDA (US)[2]. How care is paid for in these countries: provincial health insurance (Canada)[3] and Medicare and Medicaid (US)[4]. ClinicalTrials.gov lists 27 studies on RNA Interference Therapeutics that are recruiting, active or about to start in North America.[5]
[5]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RNA Interference Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Molecule
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Alnylam Pharmaceuticals
7.2 Ionis Pharmaceuticals
7.3 Arrowhead Pharmaceuticals
7.4 Novartis
7.5 Dicerna (Novo Nordisk)
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The RNA Interference Therapeutics market can be segmented based on various criteria, including molecule, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in RNA Interference Therapeutics right now, from free public sources.
Clinical trials
27 active trials in US and Canada
Recruiting, about to start, or running now. Counted across the 2 countries we report on in North America.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the RNA Interference Therapeutics market in North America?
Placeholder estimate: about $3.15 Bn in 2025, rising to about $14.94 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the RNA Interference Therapeutics market in North America growing?
Placeholder estimate: about 18.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the RNA Interference Therapeutics market report cover?
The report splits the market by molecule (siRNA, Antisense Oligonucleotides, microRNA), indication (Rare Genetic Diseases, Cardiovascular, Liver Diseases, Neurology) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the RNA Interference Therapeutics market?
Key players include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis AG and Dicerna (Novo Nordisk).
What is driving the RNA Interference Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the RNA Interference Therapeutics market.
How many clinical trials on RNA Interference Therapeutics are running in North America?
27 studies are recruiting, active or about to start in North America, counted across the 2 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
How much research is published on RNA Interference Therapeutics?
PubMed lists 28 papers on RNA Interference Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
UK
France
Brazil
Italy
Ecuador
Saudi Arabia
Spain
India
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
Regeneron Pharmaceuticals